SIBP-04 (bevacizumab biosimilar) / Sinopharm - LARVOL DELTA

A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=512 | Completed | Sponsor: Shanghai Institute Of Biological Products | Recruiting ➔ Completed | Trial completion date: Sep 2022 ➔ Jan 2023

Combination therapy • Metastases • Trial completion • Trial completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1

A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=88 | Completed | Sponsor: Shanghai Institute Of Biological Products | Unknown status ➔ Completed

Trial completion

Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non-squamous non-small cell lung cancer after bevacizumab treatment. (PubMed, Asia Pac J Clin Oncol) - "For patients with post-therapy cavitation, mRECIST exhibited higher predictability of survival than RECIST1.1. Response assessment might be improved by incorporating cavitation into assessment, potentially altering outcomes of key clinical efficacy parameters."

Journal • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial. (PubMed, J Cancer Res Clin Oncol) - P3 | "Bevacizumab combined with chemotherapy significantly prolonged the PFS and OS of advanced nsqNSCLC patients with EGFR mutation."

Clinical • Journal • Metastases • P3 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=512 | Recruiting | Sponsor: Shanghai Institute Of Biological Products

Combination therapy • New P3 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1